Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Plasmacytoma 2Paraproteinemias 2Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Patient Preference 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1CD20-positive Hematological Malignancies 1Bile Duct Neoplasms 1Advanced Solid Tumors 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × Injections, Subcutaneous × Clear all
NCT00833326 2020-10-06

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Array BioPharma

Phase 1 Completed
27 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡